Evidence map›Paper›PMID 40974097›Full record

ArticleJournal of leukocyte biology2025

Transcriptome-wide Mendelian randomization exploring dynamic CD4+ T cell gene expression in colorectal cancer development.

Benedita Deslandes, Xueyan Wu, Matthew A Lee, Lucy J Goudswaard, Gareth W Jones, Andrea Gsur, Annika Lindblom, Shuji Ogino, Veronika Vymetalkova, Alicja Wolk and 13 more

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Benedita DeslandesMRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom.ORCID 0009-0000-2738-4794
Xueyan WuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 227 South Chongqing Road, Shanghai, China.
Matthew A LeeNutrition and Metabolism Branch, International Agency for Research on Cancer, WHO, 150 cours Alber Thomas, Lyon 69372 CEDEX 08, France.
Lucy J GoudswaardMRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom.
Gareth W JonesSchool of Cellular and Molecular Medicine, University of Bristol, Biomedical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom.
Andrea GsurCenter for Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna 1090, Austria.ORCID 0000-0002-9795-1528
Annika LindblomDepartment of Clinical Genetics, Karolinska University Hospital, Solna, Stockholm 171 64, Sweden.
Shuji OginoProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, United States.ORCID 0000-0002-3909-2323
Veronika VymetalkovaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 142 20, Czech Republic.
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, Solna, Stockholm, Sweden.ORCID 0000-0001-7387-6845
Anna H WuDepartment of Population and Public Health Sciences, University of Southern California, 1845 N Soto St, Los Angeles, CA 90032, United States.ORCID 0000-0003-0546-902X
Jeroen R HuyghePublic Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave., Seattle, WA 98109-1024, United States.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave., Seattle, WA 98109-1024, United States.ORCID 0000-0001-5666-9318
Amanda I PhippsPublic Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave., Seattle, WA 98109-1024, United States.
Claire E ThomasPublic Health Sciences Division, Fred Hutchinson Cancer Center, 1100 Fairview Ave., Seattle, WA 98109-1024, United States.
Rish K PaiDepartment of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Pathology Research Core, Mayo Clinic, 13400 E. Shea Blvd., Scottsdale, AZ 85259, United States.
Robert C GrantDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Ave, Toronto, Canada ON M5G 2M9.
Daniel D BuchananDepartment of Clinical Pathology, Colorectal Oncogenomics Group, The University of Melbourne, VCCC Building, Level 10/305 Grattan St, Parkville, VIC 3010, Australia.
James YarmolinskyCancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom.
Marc J GunterNutrition and Metabolism Branch, International Agency for Research on Cancer, WHO, 150 cours Alber Thomas, Lyon 69372 CEDEX 08, France.
Jie ZhengDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 227 South Chongqing Road, Shanghai, China.ORCID 0000-0002-4265-6695
Emma HazelwoodMRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom.ORCID 0000-0002-4888-6037
Emma E VincentMRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom.

Funding

Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Transdisciplinary Studies of Genetic Variation in Colorectal CancerU19CA148107 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GRUBER, STEPHEN B · 2010 to 2014
$11.1M
MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCERR01CA081488 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRUBER, STEPHEN B · 1999 to 2008
$9.2M
Genomic Wide Association Study of Colorectal CancerU01CA122839 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CASEY, GRAHAM · 2006 to 2010
$7.3M
Cancer Research UK 25 C18281/A29019Cancer Research UK Population Research Committee C18281/A30905CRUK Integrative Cancer Epidemiology Programme C18281/A29019Medical Research Council MC_UU_00032/03Ministry of Health of the Czech Republic AZV NU22J-03-00033National Institute for Cancer Research LX22NPO5102NCI NIH HHS R01 CA081488NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA167551NCI NIH HHS U19 CA148107NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INIH HHS HHSN268201200008INIH HHS R01 CA143247NIH HHS R01 CA81488NIH HHS U01 CA122839NIH HHS U01 CA167551NIH HHS U19 CA148107University of BristolWellcome TrustWellcome Trust 218495/Z/19/ZWorld Health Organization 001
6 · The paper itself

Abstract

Recent research suggests higher circulating lymphocyte counts may protect against colorectal cancer (CRC). However, the role of specific lymphocyte subtypes and activation states remain unclear. CD4+ T cells-a highly dynamic lymphocyte subtype-undergo gene expression changes upon activation that are critical to their effector function. Previous studies using bulk tissue have limited our understanding of their role in CRC risk to static associations. We applied Mendelian randomization (MR) and genetic colocalisation to evaluate causal relationships of gene expression on CRC risk across multiple CD4+ T cell subtypes and activation states. Genetic proxies were obtained from single-cell transcriptomic data, allowing us to investigate the causal effect of expression of 1,805 genes across CD4+ T cell activation states on CRC risk (78,473 cases; 107,143 controls). Analyses were stratified by CRC anatomical subsites and sex, with sensitivity analyses assessing whether the observed effect estimates were likely to be CD4+ T cell-specific. We identified 6 genes-FADS2, FHL3, HLA-DRB1, HLA-DRB5, RPL28, and TMEM258-with strong evidence for a causal role in CRC development (FDR-P < 0.05; colocalisation H4 > 0.8). Causal estimates varied by CD4+ T cell subtype, activation state, CRC subsite and sex. However, many of genetic proxies used to instrument gene expression in CD4+ T cells also act as eQTLs in other tissues, highlighting the challenges of using genetic proxies to instrument tissue-specific expression changes. We demonstrate the importance of capturing the dynamic nature of CD4+ T cells in understanding CRC risk, and prioritize genes for further investigation in cancer prevention.

Indexed as

CD4-Positive T-LymphocytesColorectal NeoplasmsGene Expression Regulation, NeoplasticMendelian Randomization AnalysisTranscriptomeFemaleGenetic Predisposition to DiseaseHumansLymphocyte ActivationMaleCD4+ T cellscolorectal cancergene expressiongenetic epidemiologyMendelian randomization

Identifiers

PMID40974097
PMCPMC12571111

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.